Biomedical applications of microbially engineered polyhydroxyalkanoates: an insight into recent advances, bottlenecks, and solutions
- 15 January 2019
- journal article
- review article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 103 (5) , 2007-2032
Abstract
Biopolymeric polyhydroxyalkanoates (PHAs) are fabricated and accumulated by microbes under unbalanced growth conditions, primarily by diverse genera of bacteria. Over the last two decades, microbially engineered PHAs gained substantial interest worldwide owing to their promising wide-range uses in biomedical field as biopolymeric biomaterials. Because of non-hazardous disintegration products, preferred surface alterations, inherent biocompatibility, modifiable mechanical properties, cultivation support for cells, adhesion devoid of carcinogenic impacts, and controllable biodegradability, the PHAs like poly-3-hydroxybutyrate, 3-hydroxybutyrate and 3-hydroxyvalerate co-polymers, 3-hydroxybutyrate and 4-hydroxybutyrate co-polymers, etc., are available for various medical applications. These PHAs have been exploited to design in vivo implants like sutures as well as valves for direct tissue repairing as well as in regeneration devices like bone graft substitutes, nerve guides as well as cardiovascular patches, etc. Furthermore, they are also emerged as attractive candidates for developing effective/novel drug delivery systems because of their biocompatibility and biodegradability with the ability to deliver and release the drugs at a specific site in a controllable manner and, therefore widen the therapeutic window with reduced side effects. However, there still remain some bottlenecks related to PHA purity, mechanical properties, biodegradability, etc., that are need to be addressed so as to make PHAs a realistic biomaterial. In addition, innovative approaches like PHAs co-production with other value-added products, etc., must be developed currently for economical PHA production. This review provides an insight toward the recent advances, bottlenecks, and potential solutions for prospective biomedical applications of PHAs with conclusion that relatively little research/study has been performed presently toward the viability of PHAs as realistic biopolymeric biomaterials.Keywords
This publication has 173 references indexed in Scilit:
- Novel Poly(3-hydroxyoctanoate)/Poly(3-hydroxybutyrate) blends for medical applicationsReactive and Functional Polymers, 2013
- Morphology and Properties of Injection Molded Solid and Microcellular Polylactic Acid/Polyhydroxybutyrate-Valerate (PLA/PHBV) BlendsIndustrial & Engineering Chemistry Research, 2013
- Advances in the Applications of Polyhydroxyalkanoate Nanoparticles for Novel Drug Delivery SystemBioMed Research International, 2013
- Electrospun tubular scaffolds: On the effectiveness of blending poly(ε‐caprolactone) with poly(3‐hydroxybutyrate‐co‐3‐hydroxyvalerate)Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2012
- Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primatesEuropean Heart Journal, 2011
- Enatiomerically pure hydroxycarboxylic acids: current approaches and future perspectivesApplied Microbiology and Biotechnology, 2010
- Increased diversification of polyhydroxyalkanoates by modification reactions for industrial and medical applicationsApplied Microbiology and Biotechnology, 2007
- The mechanical properties and in vitro biodegradation and biocompatibility of UV-treated poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)Biomaterials, 2006
- Effect of composition of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) on growth of fibroblast and osteoblastBiomaterials, 2005
- Polymers for biodegradable medical devices. IV. Hydroxybutyrate-valerate copolymers as non-disintegrating matrices for controlled-release oral dosage formsInternational Journal of Pharmaceutics, 1987